May 2024 - Page 18 of 21

TuesdayMay 07, 2024 2:12 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the…

TuesdayMay 07, 2024 2:04 pm

QualityStocksNewsBreaks – GEMXX Corporation (GEMZ) Announces Expansion Efforts, Appoints New Board Member

GEMXX (OTC: GEMZ), a leading provider of exquisite gemstone jewelry, is expanding its business model to include private equity funding for oil and gas (“O&G”) exploration. According to the announcement, the company is leveraging already-established relationships around the world as well as newly formed strategic partnerships to create a new business channel designed to fund exploration of giant (500 million barrels) and super-giant (3 billion+ barrels) oil fields located in Latin America. This strategic decision allows the company to “tap into moderate-risk, high-reward onshore O&G opportunities,” the announcement noted. GEMXX will be focused on overlooked and underexplored basins. As part…

TuesdayMay 07, 2024 12:00 pm

DGE 8th Decentralized & Hybrid Clinical Trials Conference to be Held in Philadelphia, PA

Executives and professionals of the biopharma and medical device realm are invited to attend the 8th Decentralized & Hybrid Clinical Trial conference organized by DGE, May 15-16, 2024, in Philadelphia, PA. The event focuses on optimizing the technical processes, regulatory compliance, and design adaptability of remote clinical trials. The conference is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, healthcare, medical devices, and allied industries. During COVID-19, remote and decentralized clinical trials (DCTs) came into practice. Since then, the application…

TuesdayMay 07, 2024 11:15 am

Golden Triangle Ventures Inc. (GTVH) New Acquisition Takes Lavish Division One Step Closer to Development of Premier Music, Art Destination

More than half of Americans have attended a music festival, indicating lucrative potential for music and art destinations GTVH recently closed on the acquisition of ABI Create, a premier event-management and production company With the invaluable resources ABI Create brings to the table, the future of Destino Ranch looks more promising than ever With Coachella still fresh in music lovers’ memories, it’s only natural to look at what other amazing music festivals might be looming in the future. Destino Ranch comes to mind. A new project focused on becoming an international destination where nature and technology combine to create unforgettable…

TuesdayMay 07, 2024 10:30 am

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) Soft Bait – New York’s Answer to the Growing Rat Problem

SenesTech’s Evolve(TM) Soft Bait has been proposed to be used in New York City to control its growing rat population In a bill tabled by Upper West Side Council Member Shaun Abreu, the city will explore contraception for rats and will start with a 10-block area SenesTech’s CTO notes that the city should see close to complete elimination of the population in 12-18 months, not by just controlling the death rate, but by controlling the birth rate as well For SenesTech, this move helps affirm the superiority of its products. In addition, it serves as a sign of even bigger…

TuesdayMay 07, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024 GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings…

TuesdayMay 07, 2024 9:00 am

SuperCom Ltd. (NASDAQ: SPCB) Preparing to Deliver on $5 Million in New Sales Orders for European Electronic Monitoring Officials

The growing call for court-administered electronic monitoring services remains, as evidenced by a recent deadly Pacific Northwest domestic violence case in which a judge had previously denied a victim’s petition for requiring the suspect to wear an ankle monitor Israel-based SuperCom Ltd. has dedicated its suite of PureSecurity products to help governments economically track and monitor individuals at risk for initiating new dangerous situations The company has focused its recent efforts on the North American market, while also making inroads in Europe where it recently received over $5 million in sales orders that it will fulfill over the next few…

MondayMay 06, 2024 3:32 pm

QualityStocksNewsBreaks – Cemtrex Inc. (NASDAQ: CETX) Closes on Upsized Underwritten Public Offering Worth $10M

Cemtrex (NASDAQ: CETX), an advanced-security technology and industrial services company, has closed on a firm-commitment underwritten public offering. According to the announcement, the company will receive an estimated $10 million in gross proceeds from the offering, before standard deductions and expenses. Upsized from an original $9 million commitment, the base offering consisted of 11,764,705 common units or prefunded units; the purchase price of each common unit was $0.85, and the purchase price of each prefunded unit was $0.849. Cemtrex anticipates using the net proceeds from the offering for operations as well as to increase marketing efforts and invest in existing…

MondayMay 06, 2024 3:20 pm

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change

Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on April 30, 2024, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. In the letter, Nasdaq notified the company that, due to its non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the company's American Depositary Shares (“ADSs”) would be scheduled for delisting from the Nasdaq Capital Market and would be suspended…

MondayMay 06, 2024 3:06 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, related to its mode of action and performance. According to the announcement, the research will be conducted in partnership with the National Research Council of Canada (“NRC”). “We are excited about our partnership with the NRC for the mode of action molecular characterization of DehydraTECH-GLP-1 drugs. This work program could potentially provide data to assist Lexaria’s efforts in partnering with the pharmaceutical industry for the most rapid…

Site Search

Company Search

Month: May 2024